ABK-CDK-1
/ Abbisko
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 13, 2025
Discovery of ABK-CDK-1, a selective and brain penetrant CDK4/2 inhibitor to overcome resistance of CDK4/6 inhibitors in breast cancer
(AACR-NCI-EORTC 2025)
- "However, the clinical benefit of first-generation CDK4/6 inhibitors—such as palbociclib, ribociclib, and abemaciclib—is limited by CDK6-mediated toxicity and the emergence of resistance driven in part by cyclin E/CDK2 activation. ABK-CDK-1, developed by Abbisko Therapeutics, is a novel selective and brain-penetrant CDK4/2 inhibitor with the potential to address limitations of current CDK4/6 inhibitors. Its promising efficacy, selectivity, and other properties support further preclinical advancement toward clinical development."
Breast Cancer • Estrogen Receptor Positive Breast Cancer • Eye Cancer • Hormone Receptor Breast Cancer • Oncology • Retinoblastoma • Solid Tumor • CDK1
1 to 1
Of
1
Go to page
1